Samuel L Aitken - Concepedia

Author

Samuel L Aitken

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

Aitken, Samuel L, S Aitken, S. Aitken, S. L. Aitken, S.L. Aitken, Sam Aitken, Samuel L. Aitken, Samuel Aitken, Samuel L Aitken, Samuel L. Aitken

195

Publications

5.1K

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center The University of Texas Health Science Center at Houston University of Houston University of Pittsburgh Baylor College of Medicine

About

Samuel L Aitken is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, infection control, and clinical microbiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	20	915
2	Health Sciences	8	8	345
3	Public Health	3	3	119
4	Epidemiology	3	3	119
5	Gastroenterology	2	2	51

Samuel L Aitken

Publications

Citations

H-Index

Page 1

	Year	Citations
Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections Pranita D. Tamma, Samuel L Aitken, Robert A. Bonomo, Clinical Infectious Diseases	2023	631
Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and <i>Pseudomonas aeruginosa</i> with Difficult-to-Treat Resistance (DTR-<i>P. aeruginosa</i>) Pranita D. Tamma, Samuel L Aitken, Robert A. Bonomo, Clinical Infectious Diseases	2022	458
Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and <i>Pseudomonas aeruginosa</i> with Difficult-to-Treat Resistance (DTR-<i>P. aeruginosa</i>) Pranita D. Tamma, Samuel L Aitken, Robert A. Bonomo, Clinical Infectious Diseases	2020	405
Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and<i>Pseudomonas aeruginosa</i>with Difficult-to-Treat Resistance (DTR-<i>P. aeruginosa</i>) Pranita D. Tamma, Samuel L Aitken, Robert A. Bonomo, Clinical Infectious Diseases	2021	376
Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa José M. Munita, Samuel L Aitken, William R. Miller, Clinical Infectious Diseases Multicenter EvaluationAntimicrobial ChemotherapyDrug ResistanceAntimicrobial StewardshipTreatment Failure	2017	134
American Society for Transplantation and Cellular Therapy Series: #3—Prevention of Cytomegalovirus Infection and Disease After Hematopoietic Cell Transplantation Morgan Hakki, Samuel L Aitken, Lara Danziger‐Isakov, Transplantation and Cellular Therapy	2021	112
Oral Versus Aerosolized Ribavirin for the Treatment of Respiratory Syncytial Virus Infections in Hematopoietic Cell Transplant Recipients Farnaz Foolad, Samuel L Aitken, Terri Lynn Shigle, Clinical Infectious Diseases	2018	100
Real-Life Assessment of the Safety and Effectiveness of the New Tablet and Intravenous Formulations of Posaconazole in the Prophylaxis of Invasive Fungal Infections via Analysis of 343 Courses Frank Tverdek, Sang Taek Heo, Samuel L Aitken, Antimicrobial Agents and Chemotherapy Clinical MycologyPharmacotherapyDrug ResistanceAcute Myeloid LeukemiaDrug Monitoring	2017	88
Precision pharmacotherapy: Integrating pharmacogenomics into clinical pharmacy practice J. Kevin Hicks, Christina L. Aquilante, Henry M. Dunnenberger, JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY Translational MedicineClinical PharmacistsMedicineAmerican CollegePharmaceutical Practice	2019	81
Successful Treatment of Bloodstream Infection Due to Metallo-β-Lactamase-Producing Stenotrophomonas maltophilia in a Renal Transplant Patient María F. Mojica, Christopher P. Ouellette, Amy L. Leber, Antimicrobial Agents and Chemotherapy	2016	80

Page 1